<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486823</url>
  </required_header>
  <id_info>
    <org_study_id>11-BI-204-02</org_study_id>
    <nct_id>NCT01486823</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects</brief_title>
  <official_title>An Open-label, Single-dose Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioInvent International AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in healthy volunteers designed to investigate the PK following intravenous
      and subcutaneous administration of MLDL1278A (also known as BI-204). The bioavalialbility of
      MLDL1278A after subcutaneous administration will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of MLDL1278A.</measure>
    <time_frame>Up to 70 days post administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of MLDL1278A.</measure>
    <time_frame>Up to 70 days post administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma clearance (CL) of MLDL1278A.</measure>
    <time_frame>Up to 70 days post administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an anti therapeutic antibody (ATA) response.</measure>
    <time_frame>Up to 140 days post administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>Up to 140 days post administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLDL1278A</intervention_name>
    <description>Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLDL1278A</intervention_name>
    <description>Single subcutaneous dose of 360 mg MLDL1278A.</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males/females aged 18 to 55 years inclusive at screening;

          -  Subjects who are between 18.0 and 30.0 kg/m2 body mass index (BMI) inclusive and weigh
             between 55.0 and 100.0 kg inclusive;

        Exclusion Criteria:

          -  Any clinically relevant disease or disorder (past or present), which, in the opinion
             of the investigator, may either put the subject at risk because of participation in
             the study, or influence the results of the study, or the subject's ability to
             participate in the study;

          -  Any clinically relevant abnormal findings in physical examination, clinical chemistry,
             haematology, coagulation, urinalysis, vital signs or ECG at baseline, which, in the
             opinion of the investigator, may put the subject at risk because of his participation
             in the study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Wilbraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Drug Research Unit at Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 1YHR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

